BrightPath Biotherapeutics Co., Ltd. (4594.T)
JPY 42.0
(5.0%)
JPY 42.0
(5.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -944.85 Million JPY | 38.28% |
| 2022 | -1.53 Billion JPY | 30.96% |
| 2021 | -2.21 Billion JPY | 32.09% |
| 2020 | -3.26 Billion JPY | -8.18% |
| 2019 | -3.01 Billion JPY | 38.42% |
| 2018 | -4.9 Billion JPY | 24.93% |
| 2017 | -6.52 Billion JPY | -31.88% |
| 2016 | -4.95 Billion JPY | -93.73% |
| 2015 | -2.55 Billion JPY | -210.23% |
| 2014 | -823.73 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -662.58 Million JPY | 29.88% |
| 2023 Q3 | -796.94 Million JPY | 25.04% |
| 2023 FY | -944.85 Million JPY | 38.28% |
| 2023 Q4 | -944.85 Million JPY | -18.56% |
| 2023 Q1 | -1.26 Billion JPY | 17.44% |
| 2023 Q2 | -1.06 Billion JPY | 15.89% |
| 2022 Q4 | -1.53 Billion JPY | 13.85% |
| 2022 Q3 | -1.77 Billion JPY | 7.15% |
| 2022 Q2 | -1.91 Billion JPY | 8.11% |
| 2022 Q1 | -2.08 Billion JPY | 6.07% |
| 2022 FY | -1.53 Billion JPY | 30.96% |
| 2021 Q1 | -2.83 Billion JPY | 13.14% |
| 2021 Q2 | -2.73 Billion JPY | 3.72% |
| 2021 Q3 | -2.38 Billion JPY | 12.72% |
| 2021 FY | -2.21 Billion JPY | 32.09% |
| 2021 Q4 | -2.21 Billion JPY | 6.96% |
| 2020 Q2 | -3.79 Billion JPY | -9.34% |
| 2020 Q3 | -3.5 Billion JPY | 7.51% |
| 2020 Q4 | -3.26 Billion JPY | 6.94% |
| 2020 FY | -3.26 Billion JPY | -8.18% |
| 2020 Q1 | -3.46 Billion JPY | -14.96% |
| 2019 Q3 | -3.59 Billion JPY | 10.56% |
| 2019 FY | -3.01 Billion JPY | 38.42% |
| 2019 Q1 | -4.38 Billion JPY | 10.54% |
| 2019 Q4 | -3.01 Billion JPY | 16.09% |
| 2019 Q2 | -4.02 Billion JPY | 8.26% |
| 2018 Q2 | -5.62 Billion JPY | 7.23% |
| 2018 Q1 | -6.06 Billion JPY | 7.16% |
| 2018 Q3 | -5.23 Billion JPY | 6.91% |
| 2018 Q4 | -4.9 Billion JPY | 6.37% |
| 2018 FY | -4.9 Billion JPY | 24.93% |
| 2017 Q4 | -6.52 Billion JPY | -65.62% |
| 2017 FY | -6.52 Billion JPY | -31.88% |
| 2017 Q1 | -4.59 Billion JPY | 7.11% |
| 2017 Q2 | -4.28 Billion JPY | 6.76% |
| 2017 Q3 | -3.94 Billion JPY | 8.06% |
| 2016 Q2 | -3.59 Billion JPY | -2.65% |
| 2016 Q1 | -3.5 Billion JPY | -37.12% |
| 2016 FY | -4.95 Billion JPY | -93.73% |
| 2016 Q4 | -4.95 Billion JPY | -23.47% |
| 2016 Q3 | -4 Billion JPY | -11.48% |
| 2015 Q4 | -2.55 Billion JPY | 8.49% |
| 2015 Q3 | -2.79 Billion JPY | -846.77% |
| 2015 Q2 | -294.96 Million JPY | 0.0% |
| 2015 FY | -2.55 Billion JPY | -210.23% |
| 2014 FY | -823.73 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 227.209% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 16.675% |
| GNI Group Ltd. | -17.93 Billion JPY | 94.731% |
| Linical Co., Ltd. | -4.46 Billion JPY | 78.83% |
| Trans Genic Inc. | -221.16 Million JPY | -327.212% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 78.497% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 80.274% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 165.911% |
| AnGes, Inc. | -3.79 Billion JPY | 75.121% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | -124.535% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 103.793% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | -89.672% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | -102.609% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 65.084% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 49.96% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 3.796% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 72.186% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 8.67% |
| Kidswell Bio Corporation | 343.58 Million JPY | 374.997% |
| PeptiDream Inc. | 3.29 Billion JPY | 128.702% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 2.851% |
| Ribomic Inc. | -2.09 Billion JPY | 55.001% |
| SanBio Company Limited | -3.78 Billion JPY | 75.068% |
| Healios K.K. | -2.19 Billion JPY | 56.856% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 63.994% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 33.323% |
| StemRIM | -8.41 Billion JPY | 88.765% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 79.826% |
| FunPep Company Limited | -1.79 Billion JPY | 47.314% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 55.775% |
| Stella Pharma Corporation | -1.11 Billion JPY | 15.593% |
| TMS Co., Ltd. | -3.44 Billion JPY | 72.586% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 82.993% |
| Cuorips Inc. | -5.56 Billion JPY | 83.009% |
| K Pharma,Inc. | -3.26 Billion JPY | 71.073% |
| Takara Bio Inc. | -32.2 Billion JPY | 97.066% |
| ReproCELL Incorporated | -2.93 Billion JPY | 67.852% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | -42.953% |
| StemCell Institute Inc. | -2.83 Billion JPY | 66.692% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 54.274% |
| CellSeed Inc. | -2.01 Billion JPY | 53.04% |